1. Home
  2. OMH vs LIXT Comparison

OMH vs LIXT Comparison

Compare OMH & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ohmyhome Limited

OMH

Ohmyhome Limited

N/A

Current Price

$1.37

Market Cap

28.7M

Sector

Finance

ML Signal

N/A

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$2.80

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMH
LIXT
Founded
2015
2005
Country
Singapore
United States
Employees
N/A
4
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.7M
25.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
OMH
LIXT
Price
$1.37
$2.80
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.5K
26.9K
Earning Date
11-28-2025
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$28.40
N/A
Revenue Next Year
$23.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$0.64
52 Week High
$4.33
$6.09

Technical Indicators

Market Signals
Indicator
OMH
LIXT
Relative Strength Index (RSI) 52.67 42.49
Support Level $1.03 $2.45
Resistance Level $1.35 $3.30
Average True Range (ATR) 0.09 0.26
MACD 0.02 0.01
Stochastic Oscillator 75.61 33.73

Price Performance

Historical Comparison
OMH
LIXT

About OMH Ohmyhome Limited

Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: